EX-99.1 2 tm2037210d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

EUCRATES BIOMEDICAL ACQUISITION CORPORATION

BALANCE SHEET
OCTOBER 27, 2020

 

 

   October 27, 2020   Pro Forma Adjustments   As Adjusted 
       (unaudited)   (unaudited) 
ASSETS               
Current assets               
Cash  $711,200   $—   $711,200 
Prepaid expenses and other current assets   520,400    —    520,400 
Total Current Assets   1,231,600    —    1,231,600 
                
Cash held in Trust Account   100,000,000    4,796,260    104,796,260 
Total Assets  $101,231,600   $4,796,260   $106,027,860 
                
LIABILITIES AND STOCKHOLDERS’ EQUITY               
Current Liabilities               
Accrued expenses  $2,140   $—   $2,140 
Accrued offering costs   114,610    —    114,610 
   Total Current Liabilities   116,714    —    116,714 
                
Deferred underwriting fee payable   3,500,000    167,869    3,667,869 
Total Liabilities   3,616,714    167,869    3,784,583 
                
Commitments and Contingencies               
                
Ordinary shares subject to possible redemption, 9,261,488 and 9,724,327 shares at redemption value, respectively   92,614,880    4,628,390    97,243,270 
                
Stockholders’ Equity               
Ordinary shares, no par value; unlimited shares authorized; 3,963,512 and 3,734,798 shares issued and outstanding (excluding 9,261,488 and 9,724,327 shares subject to possible redemption), respectively   5,004,938    1    5,004,939 
Accumulated deficit   (4,932)   —    (4,932)
Total Shareholders’ Equity   5,000,006    1    5,000,007 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY  $101,231,600   $4,796,260   $106,027,860